Last July, we presented our results for the first six months of this year, where the company reflects that it complies with the expected growth plan. This increase has been mainly driven by the strength of the contract manufacturing business and by the pharmaceutical specialties business, demonstrating our continuous improvement in health matters and the importance of continuing on the path of improving the quality of patient’s life.

ROVI's operating income has increased by 31% to 380.4 million euro. This achievement is mainly marked by the growth in 76% of contract manufacturing business for third parties. In addition, the advancement of the pharmaceutical specialty business is another pillar of the company, whose sales have reached 9%.

In financial terms, ROVI has increased its EBITDA or gross operating profit by 56%, compared to the same period in 2021, to reach 115.8 million euro. Likewise, net profit has grown by 58%, up to 80.6 million euro.

This continuous growth of the company is also possible thanks to the diversification of the company's investments and the effort in different areas. The results of the business divisions in which ROVI participates have also yielded great benefits.

• Sales of prescription pharmaceuticals have increased by 9 per cent to €193.3 million.
• The heparin division increased by 8%, to 141.6 million euro.
• The biosimilar of enoxaparin increased by 31%, to 82.1 million euros, and was launched in 5 new countries in the first half of 2022.
• Sales of low molecular weight heparins have also increased by 8% and reached 137.9 million euro.

ROVI's sales outside Spain are another source of income and have increased by 48% to 248.4 million euro.

ROVI's current investment in research and development (R&D) is mainly linked to its commitment to the ISM® platform, an injectable extended-release technology of its own development.

After receiving marketing authorisation in Europe, Laboratorios ROVI has launched Risperidone ISM® in Germany and the United Kingdom, a medicine indicated for schizophrenia in adults. After this success, the company is now immersed in the regulatory process to obtain marketing authorization from its first candidate, Risperidone ISM®, in the United States. On the other hand, its second bet, Letrozol ISM®, indicated for breast cancer, yields very positive results in its phase 1 study, and the company has initiated discussions with the FDA to review these results, as well as the next steps to continue its clinical development.